Remission of Nephrotic Syndrome After Therapy for Chronic Hepatitis C Virus Infection in a Patient With Systemic Lupus Erythematosus
Authors: Hiroyuki Nakamura, Yuichiro Fujieda, Shinsuke Yasuda, Masato Nakai, Tatsuya Atsumi
Journal: Annals of Internal Medicine (2018)

Letters4 September 2018Remission of Nephrotic Syndrome After Therapy for Chronic Hepatitis C Virus Infection in a Patient With Systemic Lupus ErythematosusHiroyuki Nakamura, MD, Yuichiro Fujieda, MD, PhD, Shinsuke Yasuda, MD, PhD, Masato Nakai, MD, PhD, and Tatsuya Atsumi, MD, PhDHiroyuki Nakamura, MDHokkaido University, Sapporo, Japan (H.N., Y.F., S.Y., M.N., T.A.), Yuichiro Fujieda, MD, PhDHokkaido University, Sapporo, Japan (H.N., Y.F., S.Y., M.N., T.A.), Shinsuke Yasuda, MD, PhDHokkaido University, Sapporo, Japan (H.N., Y.F., S.Y., M.N., T.A.), Masato Nakai, MD, PhDHokkaido University, Sapporo, Japan (H.N., Y.F., S.Y., M.N., T.A.), and Tatsuya Atsumi, MD, PhDHokkaido University, Sapporo, Japan (H.N., Y.F., S.Y., M.N., T.A.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/L17-0759 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Systemic lupus erythematosus is an autoimmune disorder. Type I interferon plays an important role in this disease by promoting differentiation of B cells into plasmablasts, which produce autoantibodies. Type I interferon is a cytokine that is produced mainly by plasmacytoid dendritic cells whose usual role is to recognize nucleic acid antigens from invading viruses and initiate a response (1). This response takes place during infection with hepatitis C virus (HCV). Some cases of HCV infection can be treated by administering additional interferon, but a different treatment should be used when the patient already has a systemic autoimmune disease to ...References1. Menon M, Blair PA, Isenberg DA, Mauri C. A regulatory feedback between plasmacytoid dendritic cells and regulatory B cells is aberrant in systemic lupus erythematosus. Immunity. 2016;44:683-97. [PMID: 26968426] doi:10.1016/j.immuni.2016.02.012 CrossrefMedlineGoogle Scholar2. Mitwalli AH, Hayat A, Alwakeel J, Hammad D. Effects of concomitant hepatitis C virus infection in patients with underlying lupus nephritis on long-term renal outcome. Nephrol Dial Transplant. 2012;27:627-32. [PMID: 21771749] doi:10.1093/ndt/gfr327 CrossrefMedlineGoogle Scholar3. Castellano G, Cafiero C, Divella C, Sallustio F, Gigante M, Pontrelli P, et al. Local synthesis of interferon-alpha in lupus nephritis is associated with type I interferons signature and LMP7 induction in renal tubular epithelial cells. Arthritis Res Ther. 2015;17:72. [PMID: 25889472] doi:10.1186/s13075-015-0588-3 CrossrefMedlineGoogle Scholar4. Rose T, Grützkau A, Hirseland H, Huscher D, Dähnrich C, Dzionek A, et al. IFNa and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Ann Rheum Dis. 2013;72:1639-45. [PMID: 23117242] doi:10.1136/annrheumdis-2012-201586 CrossrefMedlineGoogle Scholar5. Imaizumi T, Aizawa T, Hayakari R, Xing F, Meng P, Tsuruga K, et al. Tumor necrosis factor-a synergistically enhances polyinosinic-polycytidylic acid-induced toll-like receptor 3 signaling in cultured normal human mesangial cells: possible involvement in the pathogenesis of lupus nephritis. Clin Exp Nephrol. 2015;19:75-81. [PMID: 24627031] doi:10.1007/s10157-014-0956-3 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Hokkaido University, Sapporo, Japan (H.N., Y.F., S.Y., M.N., T.A.)Acknowledgment: The authors thank Dr. Yuichiro Fukasawa for his contribution to the pathologic diagnosis of this patient.Financial Support: None.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L17-0759.This article was published at Annals.org on 1 May 2018. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byLAMP3 inhibits autophagy and contributes to cell death by lysosomal membrane permeabilizationEffectiveness and safety of chronic hepatitis C treatment with direct-acting antivirals in patients with rheumatic diseases: A case-series 4 September 2018Volume 169, Issue 5Page: 352-353KeywordsAntibodiesAntinuclear antibodiesAntiviral therapyDNAInterferonsLupus erythematosusLupus nephritisNecrosisRNASerum proteins ePublished: 1 May 2018 Issue Published: 4 September 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...